G6, now the previous-generation version of the company’s CGM after the launch of the G7, uses a small, wearable sensor. It also features a transmitter, continuously measuring and sending glucose levels wirelessly to a smart device or receiver. The system enables people with diabetes to receive real-time glucose data without needing to scan or prick their finger.
Dexcom said it showcased the latest clinical evidence at the meeting in Kagoshima, Japan. The company received a non-adjunctive decision and reimbursement expansion in Japan recently based on the clinical data it provided.
“Over the last several months we have made significant progress in making Dexcom G6 more accessible and easier to use for people living with diabetes in Japan,” said Scott Moss, VP of Asia-Pacific at Dexcom. “Since the last annual JDS meeting, we have been able to secure a non-adjunctive indication for Dexcom G6, making it the only real-time CGM system in Japan that can be used to make treatment decisions without routine fingersticks.
“Additionally, the Japanese Ministry of Health, Labour and Welfare recently approved the expansion of reimbursement coverage for Dexcom G6 to include all people with diabetes who use insulin at least once a day, making real-time CGM accessible to more than a million additional people living with diabetes in Japan.”
Dexcom highlights success of G6
The company said more than 300 clinical trials demonstrate the accuracy and efficacy of its CGM technology. This means the platform is supported by more peer-reviewed research than any other system on the market, according to Dexcom.
Type 1 patients using the CGM on mealtime insulin saw a 1% HbA1c reduction after 24 weeks of regular use. Type 2 patients on mealtime insulin saw a 1.4% HbA1c reduction after more than 12 weeks of use. According to Dexcom, its CGM proved to maintain consistent accuracy even during rapid rates of glucose change.
Dexcom also says common medicines (vitamin C, paracetamol, salicylic acid) don’t interfere with the accuracy of its CGM readings.
Older users demonstrated significant A1C reductions, increased time in range and a significant decrease in experienced hypoglycemic events.
“The use of Dexcom G6 can lead to better health outcomes and quality of life for patients. All people two years of age and older with diabetes on insulin therapy should be considered candidates for using CGM,” said Dr. Hirotaka Watada, professor of Juntendo University Graduate School of Medicine, Metabolism & Endocrinology, Tokyo, Japan. “As the population of Japan continues to age, the incidence rate of diabetes among older adults is also increasing. The recent expansion of reimbursement coverage to include all people using insulin has now made Dexcom CGM available to many more older adults with diabetes in Japan, who previously would not have had access to this life-changing technology.”
